Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Plasma cell 456Lymphoid 347Other hematologic neoplasm 159Myeloid 27Genitourinary 19Dermatologic 19Gastrointestinal 15CNS 12Classical hematology 9Sarcoma 8Thoracic 6Gynecologic 6Tumor-Agnostic 5Other solid neoplasm 5Head & Neck 4Endocrine 2Breast 2NET 1

Conditions

Neoplasms 4Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Lenalidomide × Tumor-Agnostic × Clear all
NCT03113695 2022-07-05

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

University of California, San Diego

Phase 1 Completed
4 enrolled
Tumor-Agnostic

Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00046735 2019-11-18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Celgene

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT01750983 2019-02-25

Ipilimumab and Lenalidomide in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
101 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡